Erratum: Big Data in Organ Transplantation: Registries and Administrative Claims (American Journal of Transplantation (2014) 14(8) (1723–1730), (S1600613522255476), (10.1111/ajt.12777));Big data in organ transplantation: Registries and administrative claims

American Journal of Transplantation

Volumn 14, Issue 8, 2014, Pages 1723-1730

  Massie, A B ^a,b   Kuricka, L M ^a,b   Segev, D L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

NIS; registry based studies; retrospective studies; SRTR; UNOS

Indexed keywords

CLINICAL RESEARCH; DATA ANALYSIS SOFTWARE; DATA BASE; DATA COLLECTION METHOD; GRAFT RECIPIENT; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; INFORMATION PROCESSING; KIDNEY TRANSPLANTATION; ORGAN DONOR; ORGAN TRANSPLANTATION; PREDICTION; PRIORITY JOURNAL; REGISTER; REVIEW; STATISTICAL MODEL; STUDY DESIGN; SURVIVAL; UNITED STATES; FACTUAL DATABASE; GOVERNMENT; KIDNEY FAILURE, CHRONIC; METHODOLOGY; STATISTICS AND NUMERICAL DATA; TRANSPLANTATION;

DATABASES, FACTUAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MODELS, STATISTICAL; ORGAN TRANSPLANTATION; REGISTRIES; RESEARCH DESIGN; TISSUE AND ORGAN PROCUREMENT; UNITED STATES; UNITED STATES AGENCY FOR HEALTHCARE RESEARCH AND QUALITY;

EID: 84904602605     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13038     Document Type: Erratum

References (55)

1. Dickinson DM, Dykstra DM, Levine GN, Li S, Welch JC, Webb RL., Transplant data: Sources, collection and research considerations, 2004. Am J Transplant 2005; 5: 850-861.
2. Young BY, Gill J, Huang E, et al. Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: An analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol 2009; 4: 845-852.
3. Massie AB, Zeger SL, Montgomery RA, Segev DL., The effects of DonorNet 2007 on kidney distribution equity and efficiency. Am J Transplant 2009; 9: 1550-1557.
4. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010; 303: 959-966.
5. Dickinson D, Arrington C, Fant G, et al. SRTR program-specific reports on outcomes: A guide for the new reader. Am J Transplant 2008; 8: 1012-1026.
6. Massie AB, Segev DL., Rates of false flagging due to statistical artifact in CMS evaluations of transplant programs: Results of a stochastic simulation. Am J Transplant 2013; 13: 2044-2051.
7. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281-1286.
8. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294: 2726-2733.
9. Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU., The broad spectrum of quality in deceased donor kidneys. Am J Transplant 2005; 5: 757-765.
10. US Renal Data System. Researcher's guide to the USRDS database: 2011, ADR edition. Bethesda, MD: US Renal Data System, 2011.
11. Merkin SS, Cavanaugh K, Longenecker JC, Fink NE, Levey AS, Powe NR., Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among end-stage renal disease patients. J Clin Epidemiol 2007; 60: 634-642.
12. McAdams-Demarco MA, Grams ME, Hall EC, Coresh J, Segev DL., Early hospital readmission after kidney transplantation: Patient and center-level associations. Am J Transplant 2012; 12: 3283-3288.
13. McAdams-Demarco MA, Grams ME, King E, Desai NM, Segev DL., Sequelae of early hospital readmission after kidney transplantation. Am J Transplant 2014; 14: 397-403.
14. Lentine KL, Schnitzler MA, Abbott KC, Bramesfeld K, Buchanan PM, Brennan DC., Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients. Clin J Am Soc Nephrol 2009; 4: 1213-1221.
15. Segev DL, Kucirka LM, Oberai PC, et al. Age and comorbidities are effect modifiers of gender disparities in renal transplantation. J Am Soc Nephrol 2009; 20: 621-628.
16. Abbott KC, Glanton CW, Agodoa LY., Body mass index and enrollment on the renal transplant waiting list in the United States. J Nephrol 2003; 16: 40-48.
17. Kucirka LM, Grams ME, Lessler J, et al. Association of race and age with survival among patients undergoing dialysis. JAMA 2011; 306: 620-626.
18. Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 2004; 44: 353-362.
19. Garg PP, Frick KD, Diener-West M, Powe NR., Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med 1999; 341: 1653-1660.
20. Schnitzler MA, Gheorghian A, Axelrod D, L'Italien G, Lentine KL., The cost implications of first anniversary renal function after living, standard criteria deceased and expanded criteria deceased donor kidney transplantation. J Med Econ 2013; 16: 75-84.
21. Gilmore AS, Helderman JH, Ricci JF, et al. Linking the US transplant registry to administrative claims data: Expanding the potential of transplant research. Med Care 2007; 45: 529-536.
22. Buchanan P, Dzebisashvili N, Lentine KL, Axelrod DA, Schnitzler MA, Salvalaggio PR., Liver transplantation cost in the model for end-stage liver disease era: Looking beyond the transplant admission. Liver Transpl 2009; 15: 1270-1277.
23. Lentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010; 363: 724-732.
24. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP). Introduction to the HCUP Nationwide Inpatient Sample (NIS) 2011. Rockville, MD: Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP), 2013.
25. Steiner C, Elixhauser A, Schnaier J., The healthcare cost and utilization project: An overview. Eff Clin Pract 2002; 5: 143-151.
26. Hollingsworth JM, Hollenbeck BK, Englesbe MJ, DeMonner S, Krein SL., Operative mortality after renal transplantation-Does surgeon type matter ? J Urol 2007; 177: 2255-2259, discussion 2259.
27. Scarborough JE, Pietrobon R, Tuttle-Newhall JE, et al. Relationship between provider volume and outcomes for orthotopic liver transplantation. J Gastrointest Surg 2008; 12: 1527-1533.
28. Pant C, Anderson MP, O'Connor JA, Marshall CM, Deshpande A, Sferra TJ., Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: Results from the 2009 Nationwide Inpatient Sample database. Transpl Infect Dis 2012; 14: 540-547.
29. Friedman AL, Cheung K, Roman SA, Sosa JA., Early clinical and economic outcomes of patients undergoing living donor nephrectomy in the United States. Arch Surg 2010; 145: 356-362, discussion 362.
30. Boyarsky BJ, Hall EC, Singer AL, Montgomery RA, Gebo KA, Segev DL., Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transplant 2011; 11: 1209-1217.
31. Herring AA, Woolhandler S, Himmelstein DU., Insurance status of U.S. organ donors and transplant recipients: The uninsured give, but rarely receive. Int J Health Serv 2008; 38: 641-652.
32. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP). Introduction to the HCUP State Inpatient Databases (SID). Rockville, MD: Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP), 2013.
33. Nathan H, Cameron JL, Choti MA, Schulick RD, Pawlik TM., The volume-outcomes effect in hepato-pancreato-biliary surgery: Hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg 2009; 208: 528-538.
34. Patel S, Orloff M, Tsoulfas G, et al. Living-donor liver transplantation in the United States: Identifying donors at risk for perioperative complications. Am J Transplant 2007; 7: 2344-2349.
35. Axelrod DA, Gheorghian A, Schnitzler MA, et al. The economic implications of broader sharing of liver allografts. Am J Transplant 2011; 11: 798-807.
36. Salvalaggio PR, Dzebisashvili N, MacLeod KE, et al. The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl 2011; 17: 233-242.
37. Muzaale AD, Massie AB, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. JAMA 2014; 311: 579-586.
38. Dekkers OM, von Elm E, Algra A, Romijn JA, Vandenbroucke JP., How to assess the external validity of therapeutic trials: A conceptual approach. Int J Epidemiol 2010; 39: 89-94.
39. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
40. Massie AB, Caffo B, Gentry SE, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011; 11: 2362-2371.
41. Simpkins CE, Montgomery RA, Hawxby AM, et al. Cold ischemia time and allograft outcomes in live donor renal transplantation: Is live donor organ transport feasible ? Am J Transplant 2007; 7: 99-107.
42. Greenland S, Finkle WD., A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995; 142: 1255-1264.
43. Vittinghoff EGDV, Shiboski SC, McCulloch CE., Regression methods in biostatistics: Linear, logistic, survival, and repeated measures models. New York: Springer, 2005.
44. Meier-Kriesche HU, Kaplan B., Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 2002; 74: 1377-1381.
45. Thompson D, Waisanen L, Wolfe R, Merion RM, McCullough K, Rodgers A., Simulating the allocation of organs for transplantation. Health Care Manag Sci 2004; 7: 331-338.
46. Gleisner AL, Munoz A, Brandao A, et al. Survival benefit of liver transplantation and the effect of underlying liver disease. Surgery 2010; 147: 392-404.
47. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
48. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: The Kidney Donor Risk Index. Transplantation 2009; 88: 231-236.
49. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P., Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187.
50. Altman DG, Vergouwe Y, Royston P, Moons KG., Prognosis and prognostic research: Validating a prognostic model. BMJ 2009; 338: 1432-1435.
51. Pencina MJ, D'Agostino RB Sr, Vasan RS., Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172, discussion 207-212.
52. Altman DG, Royston P., What do we mean by validating a prognostic model ? Stat Med 2000; 19: 453-473.
53. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD., Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54: 774-781.
54. Justice AC, Covinsky KE, Berlin JA., Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515-524.
55. Massie AB, Desai NM, Montgomery RA, Singer AL, Segev DL., Improving distribution efficiency of hard-to-place deceased donor kidneys: Predicting probability of discard or delay. Am J Transplant 2010; 10: 1613-1620. Kidney Diseases